Insmed (NASDAQ: INSM) reported Q4 EPS of ($1.54), $0.37 worse than the analyst estimate of ($1.17). Revenue for the quarter came in at $263.8 million versus the consensus estimate of $208.2 million.

For earnings history and earnings-related data on Insmed (INSM) click here.